UK Medicines Information
Revised SPC: Caelyx (doxorubicin) 2mg/ml concentrate for solution for infusion
Information type:
Drug prescribing
Source:
Glenmark Pharmaceuticals Europe Ltd
Specialities:
Cancers
Summary
The final overall survival results of a study of Caelyx plus bortezomib versus bortezomib monotherapy in patients with multiple myeloma has been added to section 5.1 (there was no significant difference between the two arms – 33.0 vs 30.8 months, respectively).
UKMi comment
The Velcade® (bortezomib) SPC has also been updated with this information.
Related links: